Prevalence of Cardiovascular Disease in Swedish Patients With Type 2 Diabetes and in Patients Initiating on Empagliflozin

First published 09/11/2026

Last updated 09/11/2026

EU PAS number:

EUPAS1000001176

Study

Finalised

Download as PDF

Documents

Study protocol

Updated protocol

Prot_SAP_1245-0190.pdf

First published: 09/11/2026

English (255.27 KB - PDF) View document

Study results

1245-0190_Synopsis.pdf

English (214.11 KB - PDF) View document

Study report

No information provided.

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

No information provided.

Prevalence of Cardiovascular Disease in Swedish Patients With Type 2 Diabetes and in Patients Initiating on Empagliflozin

Secondary tabs

Share this page